Analysts think KZIA stock price could increase by 746%
Jun 14, 2024, 6:29 AM
-13.49%
What does KZIA do
Kazia Therapeutics Ltd, headquartered in Sydney, focuses on oncology drug development, particularly brain, renal, and liver cancers, with leading programs Paxalisib and EVT801 targeting critical cancer pathways. Paxalisib inhibits the PI3K/Akt/mTOR pathway for brain cancer, while EVT801 targets VEGFR3 to hinder tumor growth and metastasis.
3 analysts think KZIA stock price will increase by 746.47%. The current median analyst target is $2.04 compared to a current stock price of $0.24. The lowest analysts target is $2.02 and the highest analyst target is $2.10.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.